Newsroom

SAN FRANCISCO--(BUSINESS WIRE)--Farallon Capital Management L.L.C. ("Farallon") today released the results of a perception study of the shareholders and sell-side analysts of T&D Holdings Inc. ("T&D HD" or the “Company”) conducted by an independent global research firm (“Perception Study”). Farallon first became a shareholder of T&D HD in 2008 and has continued to engage constructively with T&D HD management and Board of Directors. Farallon has requested that the Company acceler...

サンフランシスコ--(BUSINESS WIRE)--（ビジネスワイヤ） -- ファラロン・キャピタル・マネジメントL.L.C.（以下「当社」）は、独立した第三者である世界的な大手グローバル調査会社に、T&Dホールディングス株式会社（以下「T&D HD」）に関する株主等意見調査（Perception Study、以下「本調査」）の実施を依頼しました。今般、当該調査会社が取りまとめた調査結果を公表いたします。 当社は2008年にT&D HDの株主となり、現在、T&D HDの経営陣および取締役会との継続的かつ建設的な対話を実施しております。このような対話の機会を得られていることに、深く感謝しております。当社は、T&D HDに対し、企業価値向上に向けた大胆な改革を遂行するとともに、経済価値ベースの指標をKPIに据えた『EV経営』を推進し、キャピタル・アロケーション戦略においても同様の観点を徹底することを求めています。 当社は、こうした対話を継続している中で、資本市場におけるT&D HDの客観的な評価を、同社の経営陣および取締役会に認識いただく...

TOKYO & MUNICH--(BUSINESS WIRE)--The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and...

CAMBRIDGE, England--(BUSINESS WIRE)--EDX Medical Group announces the commercial launch in the UK of a new comprehensive testing service that improves the early detection of bowel cancer....

DUBAÏ--(BUSINESS WIRE)--RHI Magnesita, le premier fournisseur mondial de produits, systèmes et solutions réfractaires haut de gamme, a renforcé ses activités dans la région Moyen-Orient, Turquie et Afrique (META) en créant une nouvelle unité commerciale dont le siège est à Dubaï, avec l’ambition de poursuivre sa croissance et son expansion dans la région. La société a inauguré hier son nouveau bureau régional, marquant ainsi une étape importante dans son parcours de croissance et soulignant son...

NEW YORK & PARIS--(BUSINESS WIRE)--OpenGate Capital (“OpenGate”), a global private equity firm, completed the sale of ScioTeq, a global leader in ruggedized displays for the aviation and defense industries, to the aerospace and defense fund of global alternative asset manager Tikehau Capital (ISIN code: FR0013230612; Ticker: TKO.FP). OpenGate will maintain a meaningful minority position and will continue to support the company’s next phase of growth. ScioTeq has a 40-year heritage of designing...

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announces that the Board of Directors has appointed Robert Lyne as Chief Executive Officer (CEO), and as a member of the Board of Directors, effective immediately. Robert Lyne commented: “I’m honored to lead PureTech as CEO at such an important moment in its evolution. Over...

LONDON--(BUSINESS WIRE)--  ISIN Code. XS3188669298 Our Ref. MU4314 ISSUE NAME. Commonwealth Bank of Australia Issue of GBP 200,000,000.00 Floating Rate Notes due September 2026 Series 6698 Tranche 1 MTN INTEREST PERIOD. 24/09/2025 TO 24/12/2025 VALUE DATE. 24/12/2025 INTEREST RATE. 4.30865 PCT NUM OF DAYS. 91 DAY BASIS. ACTUAL/365 FIXED (A005) CURRENCY CODE. GBP TOTAL INTEREST AMT. GBP 2,148,422.74 POOL FACTOR. N/A...

RIYADH, Saudi Arabia--(BUSINESS WIRE)--Practo announced the appointment of Satish Rao as the new General Manager for Saudi Arabia, to accelerate the expansion of Insta by Practo....

PARIS--(BUSINESS WIRE)--Regulatory News: Getlink (Paris:GET) has reached an agreement with its insurers for compensation for Eleclink’s operating losses resulting from the suspension of activity between 25 September 2024 and 5 February 2025. The total amount of compensation is €55 million, of which €5 million was already accounted for in the first half of 2025. This amount will be recognised in the Group’s consolidated financial statements in 2025. Note: the Group’s 2025 EBITDA1 guidance, set i...